FEMASYS INC. - COMMON STOCK

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

08 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

27 июн 2024 08:30:00 Источник Nasdaq GlobeNewswire

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

20 июн 2024 08:30:00 Источник Nasdaq GlobeNewswire

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

17 май 2024 08:30:00 Источник Nasdaq GlobeNewswire

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council

16 май 2024 08:30:00 Источник Nasdaq GlobeNewswire

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

09 май 2024 08:30:00 Источник Nasdaq GlobeNewswire

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

07 май 2024 08:30:00 Источник Nasdaq GlobeNewswire

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives

18 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

28 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

21 мар 2024 09:00:00 Источник Nasdaq GlobeNewswire

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

20 мар 2024 08:15:00 Источник Nasdaq GlobeNewswire

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

13 мар 2024 09:00:00 Источник Nasdaq GlobeNewswire

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

06 мар 2024 09:00:00 Источник Nasdaq GlobeNewswire

Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

28 фев 2024 09:00:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

06 фев 2024 08:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

26 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

23 янв 2024 08:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

15 дек 2023 08:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

30 ноя 2023 08:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch

28 ноя 2023 08:30:00 Источник Nasdaq GlobeNewswire